Skip to main content
. Author manuscript; available in PMC: 2018 Apr 10.
Published in final edited form as: Cancer Cell. 2017 Apr 10;31(4):471–473. doi: 10.1016/j.ccell.2017.03.012

Figure 1. Summary of Hydbring et al.

Figure 1

Through several screens, it was determined that a subset of miRNAs target cyclins and CDKs, which are positive drivers of the cell cycle. These “cell-cycle-targeting miRNAs” were found to be inversely correlated with cyclins/CDKs in The Cancer Genome Atlas (TCGA) data, as well as either reduced or deleted in several tumor types. Therapeutic efficacy of these cell-cycle-targeting miRNAs was enriched in TNBC and gastric cancer cell lines, which was validated in chemotherapy-resistant PDX models.